News

Isomorphic Labs raises $5 billion Series C led by Greenoaks and Sequoia

Isomorphic Labs raised a $5 billion Series C, more than its two previously announced external rounds combined, to expand its AI drug-design engine and therapeutic pipeline.

D
Nov 17, 2026 · 1 min read

Isomorphic Labs raised $5 billion in Series C financing, in a round co-led by Greenoaks and Sequoia Capital.

The financing is larger than the AI drug-discovery company’s two previously announced external rounds combined. Isomorphic Labs disclosed a $600 million round in March 2025 and a $2.1 billion Series B in May 2026, totaling $2.7 billion before the latest investment. Across all three rounds, the company has announced $7.7 billion in external funding.

Andreessen Horowitz joined the Series C with several unnamed new investors. Isomorphic Labs said Alphabet made another significant investment and that every existing investor participated: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company did not disclose a valuation, equity terms, ownership percentages or other pricing terms.

Isomorphic Labs said it will use the capital to develop IsoDDE further, move into new areas of biology and expand its therapeutic candidate pipeline. It describes IsoDDE as a proprietary drug-design engine that combines foundational simulation AI models across therapeutic areas and drug types.

The plans also cover global AI-led bioengineering infrastructure, along with translational and clinical-development capabilities intended to support drug candidates as they move toward clinical trials.

Thrive Capital led the company’s first external funding round, with GV participating and Alphabet providing follow-on capital. Thrive also led the $2.1 billion Series B, which included Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund.

More news